MAPK, β-amyloid and synaptic dysfunction: The role of RAGE

Expert Review of Neurotherapeutics

Volumn 9, Issue 11, 2009, Pages 1635-1645

  Origlia, Nicola ^a   Arancio, Ottavio ^b   Domenici, Luciano ^c   Yan, Shirley ShiDu ^b  

^a CNR   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

amyloid; Alzheimer's disease; Mitogen activated protein kinase; Receptor for advanced glycation end products; Synaptic dysfunction

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR INHIBITOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; ENCEPHALITIS; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; HUMAN; LONG TERM DEPRESSION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; REVIEW; SENILE PLAQUE; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; SYNAPSES;

EID: 70849085456     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.107     Document Type: Review

References (154)

1. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest. 115(5), 1121-1129 (2005). (Pubitemid 40629026)
2. Kametani F. ε-secretase: reduction of amyloid precursor protein ε-site cleavage in Alzheimer's disease. Curr. Alzheimer Res. 5(2), 165-171 (2008).
3. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE. Toxicity of various amyloid β peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant. J. Neurosci. Res. 60(6), 804-810 (2000).
4. Johnson LV, Leitner WP, Rivest AJ et al. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA 99(18), 11830-11835 (2002).
5. Stromer T, Serpell LC. Structure and morphology of the Alzheimer's amyloid fibril. Microsc. Res. Tech. 67(3-4), 210-217 (2005). (Pubitemid 41243637)
6. Cirrito JR, May PC, O'Dell MA et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23(26), 8844-8853 (2003).
7. Cirrito JR, Yamada KA, Finn MB et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48(6), 913-922 (2005). • Excellent experimental work demonstrating that synaptic transmission is able to modulate Aβ generation and its release into the extracellular space. The finding that the Aβ intracellular pool depends on synaptic activity has implications for Alzheimer's disease (AD) pathogenesis and may provide insights into therapeutic intervention.
8. Cirrito JR, Kang JE, Lee J et al. Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo. Neuron 58(1), 42-51 (2008).
9. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007). (Pubitemid 47058377)
10. Hsia AY, Masliah E, McConlogue L et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96(6), 3228-3233 (1999). (Pubitemid 29148873)
11. Chapman PF, White GL, Jones MW et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2(3), 271-276 (1999).
12. Li QX, Maynard C, Cappai R et al. Intracellular accumulation of detergent-soluble amyloidogenic A β fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J. Neurochem. 72(6), 2479-2487 (1999). (Pubitemid 29242199)
13. Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 840(1-2), 23-35 (1999). (Pubitemid 29434821)
14. Giacchino J, Criado JR, Games D, Henriksen S. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res. 876(1-2), 185-190 (2000). (Pubitemid 30706415)
15. Wirths O, Multhaup G, Czech C et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 306(1-2), 116-120 (2001). (Pubitemid 32524311)
16. Oddo S, Caccamo A, Shepherd JD et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39(3), 409-421 (2003). (Pubitemid 36937044)
17. Ingelsson M, Fukumoto H, Newell KL et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62(6), 925-931 (2004). (Pubitemid 38435780)
18. Robbins TW, Elliott R, Sahakian BJ. Neuropsychology - dementia and affective disorders. Br. Med. Bull. 52(3), 627-643 (1996).
19. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163(2), 495-529 (2000).
20. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68(3), 209-245 (2002). (Pubitemid 35346805)
21. Bartus RT, Dean RL 3rd. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl.), 202(1-3), 15-36 (2009).
22. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594), 789-791 (2002).
23. Arancio O, Zhang HP, Chen X et al. RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J. 23(20), 4096-4105 (2004). •• Excellent work showing that receptor for advanced glycation end products (RAGE) is a receptor important for development of Aβ-dependent neuronal dysfunction.
24. Origlia N, Righi M, Capsoni S et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J. Neurosci. 28(13), 3521-3530 (2008). • Good experimental work linking synaptic dysfunction induced by Aβ/RAGE signaling to phosphorylation of p38 MAPK.
25. Braak H, Braak E. Entorhinal-hippocampal interaction in mnestic disorders. Hippocampus 3, 239-246 (1993).
26. Witter MP. Organization of the entorhinal-hippocampal system: a review of current anatomical data. Hippocampus 3, 33-44 (1993).
27. Suzuki WA, Amaral DG. Functional neuroanatomy of the medial temporal lobe memory system. Cortex 40(1), 220-222 (2004).
28. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1(3), 213-216 (1991).
29. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361(6407), 31-39 (1993).
30. Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science 313(5790), 1093-1097 (2006).
31. Lambert MP, Barlow AK, Chromy BA et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95(11), 6448-6453 (1998).
32. Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid β-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem. 77(3), 354-371 (2002). (Pubitemid 34971647)
33. Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880), 535 (2002).
34. Zhao D, Watson JB, Xie CW. Amyloid β prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J. Neurophysiol. 92(5), 2853-2858 (2004). (Pubitemid 40340496)
35. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24(13), 3370-3378 (2004). (Pubitemid 38451902)
36. Walsh DM, Townsend M, Podlisny MB et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci. 25(10), 2455-2462 (2005). (Pubitemid 40365155)
37. Shankar GM, Li S, Mehta TH et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008). •• Excellent paper demonstrating that Aβ oligomeric extracts from the brain of AD patients induce synaptic dysfunction, synaptic loss and cognitive deficits.
38. Snyder EM, Nong Y, Almeida CG et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8(8), 1051-1058 (2005). (Pubitemid 41061516)
39. Tyszkiewicz JP, Yan Z. β-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J. Neurophysiol. 93(6), 3102-3111 (2005). (Pubitemid 40720893)
40. Hsieh H, Boehm J, Sato C et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52(5), 831-843 (2006). • Good experimental work linking Aβ-dependent synaptic depression to reduction of AMPA current and removal of AMPA receptors from synaptic cleft. (Pubitemid 44828454)
41. Parameshwaran K, Sims C, Kanju P et al. Amyloid β-peptide Aβ(1-42) but not Aβ(1-40) attenuates synaptic AMPA receptor function. Synapse 61(6), 367-374 (2007). (Pubitemid 46559534)
42. Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382(6593), 685-691 (1996). •• Excellent paper showing for the first time that RAGE functions as a cell surface binding site for Aβ. This work establishes an important role for Aβ engagement of RAGE in downstream signaling and effector mechanisms leading to oxidative stress, inflammation and neurotoxicity. (Pubitemid 26282167)
43. Yan SD, Yan SF, Chen X et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1(7), 693-699 (1995).
44. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498(2-3), 99-111 (2000).
45. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108(7), 949-955 (2001).
46. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis. 16(4), 833-843 (2009)
47. Yeh CH, Sturgis L, Haidacher J et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes 50(6), 1495-1504 (2001). (Pubitemid 32500185)
48. Li JH, Wang W, Huang XR et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 164(4), 1389-1397 (2004). (Pubitemid 38387804)
49. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential target for Aβ-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 7(8), 735-742 (2007).
50. Bucciarelli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59(7), 1117-1128 (2002). (Pubitemid 34895406)
51. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 550(1-3), 107-113 (2003). (Pubitemid 37281366)
52. Lue LF, Walker DG, Brachova L et al. Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171(1), 29-45 (2001). (Pubitemid 32848443)
53. Deane R, Du Yan S, Submamaryan RK et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9(7), 907-913 (2003). (Pubitemid 36889934)
54. Mucke L, Yu GQ, McConlogue L et al. Astroglial expression of human α(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol. 157(6), 2003-2010 (2000).
55. Simm A, Casselmann C, Schubert A et al. Age associated changes of AGE-receptor expression: RAGE upregulation is associated with human heart dysfunction. Exp. Gerontol. 39(3), 407-413 (2004). (Pubitemid 38264371)
56. Ding Q, Keller JN. Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 1746(1), 18-27 (2005). (Pubitemid 41484082)
57. Chaney MO, Stine WB, Kokjohn TA et al. RAGE and amyloid β interactions: atomic force microscopy and molecular modelling. Biochim. Biophys. Acta 1741(1-2), 199-205 (2005).
58. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 5(3), 173-183 (2004).
59. Costa M, Marchi M, Cardarelli F et al. Dynamic regulation of ERK2 nuclear translocation and mobility in living cells. J. Cell Sci. 119(23), 4952-4963 (2006). (Pubitemid 46017808)
60. Marchi M, D'Antoni A, Formentini I et al. The N-terminal domain of ERK1 accounts for the functional differences with ERK2. PLoS One 3(12), e3873 (2008).
61. Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD. Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn. Mem. 8(1), 11-19 (2001). (Pubitemid 32167883)
62. Mazzucchelli C, Vantaggiato C, Ciamei A et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34(5), 807-820 (2002). (Pubitemid 34628742)
63. Aouadi M, Binetruy B, Caron L, Le Marchand-Brustel Y, Bost F. Role of MAPKs in development and differentiation: lessons from knockout mice. Biochimie 88(9), 1091-1098 (2006).
64. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 14(3), 311-317 (2004).
65. Costa RM, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J. Child. Neurol. 17(8), 622-651 (2002).
66. Kanterewicz BI, Urban NN, McMahon DB et al. The extracellular signal-regulated kinase cascade is required for NMDA receptor-independent LTP in area CA1 but not area CA3 of the hippocampus. J. Neurosci. 20(9), 3057-3066 (2000).
67. Coogan AN, O'Leary DM, O'Connor JJ. P42/44 MAP kinase inhibitor PD98059 attenuates multiple forms of synaptic plasticity in rat dentate gyrus in vitro. J. Neurophysiol. 81(1), 103-110 (1999).
68. Huang YY, Martin KC, Kandel ER. Both protein kinase A and mitogen-activated protein kinase are required in the amygdala for the macromolecular synthesis-dependent late phase of long-term potentiation. J. Neurosci. 20(17), 6317-6325 (2000).
69. Schafe GE, Atkins CM, Swank MW et al. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J. Neurosci. 20(21), 8177-8187 (2000).
70. Di Cristo G, Berardi N, Cancedda L et al. Requirement of ERK activation for visual cortical plasticity. Science 292(5525), 2337-2340 (2001). (Pubitemid 32568057)
71. English JD, Sweatt JD. Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J. Biol. Chem. 271(40), 24329-24332 (1996).
72. 2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron 21(4), 869-883 (1998).
73. Pages G, Guerin S, Grall D et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286(5443), 1374-1377 (1999). (Pubitemid 129516242)
74. Samuels IS, Karlo JC, Faruzzi AN et al. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J. Neurosci. 28(27), 6983-6995 (2008).
75. Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 110(4), 443-455 (2002). (Pubitemid 35232288)
76. Webster B, Hansen L, Adame A et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 65(2), 142-151 (2006). (Pubitemid 43755378)
77. Dineley KT, Westerman M, Bui D et al. B-amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 21(12), 4125-4133 (2001). (Pubitemid 32538537)
78. Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ. Mol. Cell. Neurosci. 9(3), 220-234 (1997). (Pubitemid 27323434)
79. Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar β-amyloid in mature hippocampal neurons. J. Neurochem. 74(1), 125-133 (2000). (Pubitemid 30012762)
80. Chong YH, Shin YJ, Lee EO et al. ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem. 281(29), 20315-20325 (2006).
81. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319(3), 991-997 (2006). (Pubitemid 44776445)
82. Stanciu M, Wang Y, Kentor R et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275(16), 12200-12206 (2000). (Pubitemid 30237798)
83. Townsend M, Mehta T, Selkoe DJ. Soluble Ab inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282(46), 33305-33312 (2007). (Pubitemid 350159548)
84. Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-Vd prevents amyloid-β oligomer neurotoxicity. J. Neurosci. 28(20), 5149-5158 (2008).
85. Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J. 16(12), 3563-3571 (1997). (Pubitemid 27250050)
86. Cuenda A, Cohen P, Buee-Scherrer V, Goedert M. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J. 16(2), 295-305 (1997). (Pubitemid 27049387)
87. Kuma Y, Sabio G, Bain J et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280(20), 19472-19479 (2005). (Pubitemid 41379467)
88. Cohen PS, Schmidtmayerova H, Dennis J et al. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med. 3(5), 339-346 (1997). (Pubitemid 27295104)
89. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81(2), 807-869 (2001). (Pubitemid 32267078)
90. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773(8), 1358-1375 (2007). (Pubitemid 47125981)
91. Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat. Neurosci. 3(11), 1107-1112 (2000). (Pubitemid 30828182)
92. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270(5240), 1326-1331 (1995).
93. Kawasaki H, Morooka T, Shimohama S et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 272(30), 18518-18521 (1997). (Pubitemid 27318185)
94. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23(5), 1605-1611 (2003). (Pubitemid 36314715)
95. Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial proinflammatory cytokine IL-1β production. Neurobiol. Aging 25(4), 431-439 (2004).
96. Culbert AA, Skaper SD, Howlett DR et al. MAPK-activated protein kinase 2 deficiency in microglia inhibits proinflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 281(33), 23658-23667 (2006).
97. Zhu X, Mei M, Lee HG et al. P38 activation mediates amyloid-β cytotoxicity. Neurochem. Res. 30(6-7), 791-796 (2005). (Pubitemid 41413936)
98. Troy CM, Rabacchi SA, Xu Z et al. β-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J. Neurochem. 77(1), 157-164 (2001). (Pubitemid 32245089)
99. Coogan AN, O'Neill LA, O'Connor JJ. The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1β on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience 93(1), 57-69 (1999).
100. Kelly A, Vereker E, Nolan Y et al. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 β on long term potentiation in rat dentate gyrus. J. Biol. Chem. 278(21), 19453-19462 (2003). (Pubitemid 36799342)
101. Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 275, 7395-7402 (2000).
102. Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA 98, 13681-13686 (2001).
103. Munoz L, Ranaivo HR, Roy SM et al. A novel p38 a MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflam. 4(21), 1-14 (2007).
104. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269(13), 9889-9897 (1994).
105. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 353(6345), 670-674 (1991). (Pubitemid 21912588)
106. Derijard B, Hibi M, Wu IH et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76(6), 1025-1037 (1994). (Pubitemid 24106383)
107. Yang D, Tournier C, Wysk M et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc. Natl Acad. Sci. USA 94(7), 3004-3009 (1997). (Pubitemid 27157254)
108. Kallunki T, Su B, Tsigelny I et al. JNK2 contains a specificity- determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8(24), 2996-3007 (1994).
109. Gupta S, Barrett T, Whitmarsh AJ et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15(11), 2760-2770 (1996). (Pubitemid 26176253)
110. Chang JS, Wendt T, Qu W et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 102(8), 905-913 (2008). (Pubitemid 351591549)
111. Chen JT, Lu DH, Chia CP et al. Impaired long-term potentiation in c-Jun N-terminal kinase 2-deficient mice. J. Neurochem. 93(2), 463-473 (2005).
112. Carletti R, Tacconi S, Bettini E, Ferraguti F. Stress activated protein kinases, a novel family of mitogen-activated protein kinases, are heterogeneously expressed in the adult rat brain and differentially distributed from extracellular-signal-regulated protein kinases. Neuroscience 69(4), 1103-1110 (1995).
113. Kumagae Y, Zhang Y, Kim OJ, Miller CA. Human c-Jun N-terminal kinase expression and activation in the nervous system. Brain Res. Mol. Brain Res. 67(1), 10-17 (1999). (Pubitemid 29170063)
114. Mielke K, Herdegen T. JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 61(1), 45-60 (2000). (Pubitemid 30100402)
115. Curran BP, Murray HJ, O'Connor JJ. A role for c-Jun N-terminal kinase in the inhibition of long-term potentiation by interleukin-1β and long-term depression in the rat dentate gyrus in vitro. Neuroscience 118(2), 347-357 (2003).
116. Li XM, Li CC, Yu SS et al. JNK1 contributes to metabotropic glutamate receptor-dependent long-term depression and short-term synaptic plasticity in the mice area hippocampal CA1. Eur. J. Neurosci. 25(2), 391-396 (2007).
117. Xu X, Raber J, Yang D, Su B, Mucke L. Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. Proc. Natl Acad. Sci. USA 94(23), 12655-12660 (1997). (Pubitemid 27492584)
118. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr. Drug Targets CNS Neurol. Disord. 4(1), 63-67 (2005).
119. Silva RM, Kuan CY, Rakic P, Burke RE. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov. Disord. 20(6), 653-664 (2005). (Pubitemid 41051776)
120. Braak H, Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol. Aging 15(3), 355-380 (1994).
121. Pei JJ, Braak E, Braak H et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis. 3(1), 41-48 (2001). (Pubitemid 32238249)
122. Shoji M, Iwakami N, Takeuchi S et al. JNK activation is associated with intracellular β-amyloid accumulation. Brain Res. Mol. Brain Res. 85(1-2), 221-233 (2000). (Pubitemid 32056254)
123. Morishima Y, Gotoh Y, Zieg J et al. B-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21(19), 7551-7560 (2001). (Pubitemid 32904954)
124. Jang JH, Surh YJ. β-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann. NY Acad. Sci. 973, 228-236 (2002).
125. Wei W, Norton DD, Wang X, Kusiak JW. Aβ 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125(Pt 9), 2036-2043 (2002). (Pubitemid 34940714)
126. Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the β-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem. J. 371(Pt 3), 789-798 (2003). (Pubitemid 36578878)
127. Minogue AM, Schmid AW, Fogarty MP et al. Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-β on long term potentiation and cell death in hippocampus: a role for interleukin-1β? J. Biol. Chem. 278(30), 27971-27980 (2003).
128. Bell KA, O'Riordan KJ, Sweatt JD, Dineley KT. MAPK recruitment by β-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 91(2), 349-361 (2004).
129. Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784), 354-360 (2000). (Pubitemid 30337069)
130. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell. 4(4), 521-533 (2003). (Pubitemid 36437559)
131. Bianchi R, Giambanco I, Donato R. S100B/RAGE-dependent activation of microglia via NF-κB and AP-1 coregulation of COX-2 expression by S100B, IL-1β and TNF-α. Neurobiol. Aging (2008).
132. Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA. Modulation of amyloid-β-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J. Neurochem. 103(3), 914-926 (2007).
133. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD005593 (2006).
134. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis. 6(6 Suppl.), S61-S74 (2004).
135. Klyubin I, Wang Q, Reed MN et al. Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol. Aging (2009) (Epub ahead of print).
136. Lazarov O, Marr RA. Neurogenesis and Alzheimer's disease: at the crossroads. Exp. Neurol. DOI: 10.1016/j.expneurol.2009.08.009 (2009) (Epub ahead of print).
137. Wang JM, Irwin RW, Liu L, Chen S, Brinton RD. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr. Alzheimer Res. 4(5), 510-517 (2007). (Pubitemid 350248383)
138. Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: alloprenanaolone as a proof of concept neurogenic agent. Curr. Alzheimer Res. 3(3), 185-190 (2006).
139. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101-112 (2007). (Pubitemid 46432529)
140. Tomita T. At the frontline of Alzheimer's disease treatment: γ-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch. Pharmacol. 377(4-6), 295-300 (2008).
141. Puzzo D, Privitera L, Leznik E et al. Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28(53), 14537-14545 (2008). • Excellent experimental work demonstrating that low Aβ level is capable of modulating synaptic plasticity and cognitive functions.
142. Federoff HJ. Development of vaccination approaches for the treatment of neurological diseases. J. Comp. Neurol. 515(1), 4-14 (2009).
143. Giuffrida ML, Caraci F, Pignataro B et al. β-amyloid monomers are neuroprotective. J. Neurosci. 29(34), 10582-10587 (2009).
144. Atwood CS, Obrenovich ME, Liu T et al. Amyloid-β: a chameleon walking two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res. Brain Res. Rev. 46(1), 118-120 (2003).
145. Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity. Exp. Gerontol. 39(11-12), 1661-1667 (2004). (Pubitemid 39576137)
146. Zhu X, Rottkamp CA, Hartzler A et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. 79(2), 311-318 (2001). (Pubitemid 32988947)
147. Giovannini MG, Scali C, Prosperi C et al. β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. 11, 257-274 (2002). (Pubitemid 36135690)
148. Hensley K, Floyd RA, Zheng NY et al. P38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72, 2053-2058 (1999). (Pubitemid 29186010)
149. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp. Neurol. 183, 394-405 (2003). (Pubitemid 37205081)
150. Swatton JE, Sellers LA, Faull RL, Holland A, Iritani S, Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 19, 2711-2719 (2004). (Pubitemid 38746388)
151. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385 (2002).
152. Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox. Res. 6, 469-475 (2004).
153. Webster J, Andrews R, Shen J et al. Small-molecule inhibitors of the receptor for advanced glycation end-products (RAGE) are an effective therapy in animal models of Alzheimer's disease. Program and abstracts of the ICAD 2008: Alzheimer's Association International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.
154. Sabbagh MN, Bell J, Agro A, Aisen P, Galasko D. An oral antagonist of the receptor for advanced glycation end-products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a Phase II study. Program and abstracts of the ICAD 2008: Alzheimer's Association International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.